Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleCELLULAR AND MOLECULAR

A Novel Phenylaminotetralin Radioligand Reveals a Subpopulation of Histamine H1 Receptors

Raymond G. Booth, Nader H. Moniri, Remko A. Bakker, Neepa Y. Choksi, William B. Nix, Henk Timmerman and Rob Leurs
Journal of Pharmacology and Experimental Therapeutics July 2002, 302 (1) 328-336; DOI: https://doi.org/10.1124/jpet.302.1.328
Raymond G. Booth
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nader H. Moniri
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Remko A. Bakker
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Neepa Y. Choksi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William B. Nix
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Henk Timmerman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rob Leurs
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Previously, (−)-trans-1-phenyl-3-N,N-dimethylamino-1,2,3,4-tetrahydronaphthalene ([−]-trans-H2-PAT) was shown to activate stereospecifically histamine H1 receptors coupled to modulation of tyrosine hydroxylase activity in guinea pig and rat forebrain in vitro and in vivo. Furthermore, the novel radioligand [3H](−)-trans-H2-PAT was shown to label selectively H1 receptors in guinea pig and rat brain with high affinity (KD, ∼0.1 and 0.5 nM, respectively) and a Bmax about 50 and 15%, respectively, of that observed for the H1antagonist radioligand [3H]mepyramine. In the current study, [3H](−)-trans-H2-PAT-labeled cloned guinea pig and human H1 receptors in Chinese hamster ovary (CHO) cell membranes with high affinity (KD, ∼0.08 and 0.23 nM, respectively) and a Bmax about 15% of that observed for [3H]mepyramine. The binding of H2-PAT to H1 receptors in both CHO-H1 cell lines was stereoselective with the (−)-trans-isomer having affinity (Ki, ∼1.5 nM) about 4-, 20-, and 50-times higher than the (−)-cis-, (+)-trans-, and (+)-cis-isomers, respectively; the affinity of (−)-trans-H2-PAT was unaffected by excess GTP. In functional assays, (−)-trans-H2-PAT was a full antagonist of histamine H1-mediated stimulation of phospholipase C (PLC) and [3H]inositol phosphates (IP) formation in CHO-H1 cells, a full inverse agonist of constitutively active H1 receptors in COS-7-H1cells, and a full competitive antagonist (pA2 = 9.2) of histamine H1-mediated contraction of guinea pig ileum. It is concluded that (−)-trans-H2-PAT is an antagonist at H1 receptors coupled to PLC/IP formation and smooth muscle contraction. Meanwhile, the observation that [3H](−)-trans-H2-PAT labels only a subpopulation of H1 receptors and that (−)-trans-H2-PAT activates H1receptors coupled to modulation of tyrosine hydroxylase suggests that there may be post-translational H1 receptor heterogeneity.

Footnotes

  • This work was supported by United States Public Health Service Grant NS35216 and the Pharmacy Foundation of North Carolina.

  • Abbreviations:
    PAT
    1-phenyl-3-amino-1,2,3,4-tetrahydronaphthalenes
    GPCR
    G protein-coupled receptor
    CHO
    Chinese hamster ovary
    CHOgpH1
    CHO cells expressing cDNA for the guinea pig H1 receptor
    CHOhuH1
    CHO cells expressing cDNA for the human H1 receptor
    COShuH1
    African, green monkey kidney cells transfected with the human H1receptor
    PLC
    phospholipase C
    IP
    inositol phosphate
    NF-κB
    nuclear factor-κB
    MEM
    minimum essential medium
    DMEM
    Dulbecco's modified Eagle's medium
    • Received October 1, 2001.
    • Accepted March 22, 2002.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 302 (1)
Journal of Pharmacology and Experimental Therapeutics
Vol. 302, Issue 1
1 Jul 2002
  • Table of Contents
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
A Novel Phenylaminotetralin Radioligand Reveals a Subpopulation of Histamine H1 Receptors
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleCELLULAR AND MOLECULAR

A Novel Phenylaminotetralin Radioligand Reveals a Subpopulation of Histamine H1 Receptors

Raymond G. Booth, Nader H. Moniri, Remko A. Bakker, Neepa Y. Choksi, William B. Nix, Henk Timmerman and Rob Leurs
Journal of Pharmacology and Experimental Therapeutics July 1, 2002, 302 (1) 328-336; DOI: https://doi.org/10.1124/jpet.302.1.328

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleCELLULAR AND MOLECULAR

A Novel Phenylaminotetralin Radioligand Reveals a Subpopulation of Histamine H1 Receptors

Raymond G. Booth, Nader H. Moniri, Remko A. Bakker, Neepa Y. Choksi, William B. Nix, Henk Timmerman and Rob Leurs
Journal of Pharmacology and Experimental Therapeutics July 1, 2002, 302 (1) 328-336; DOI: https://doi.org/10.1124/jpet.302.1.328
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • N-stearoylethanolamine inhibits platelet reactivity
  • CsA Downregulates Selenop Expression via a STAT3-FoxO1 Axis
  • Anisodamine Ameliorates Acute Lung Injury
Show more Cellular and Molecular

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics